文献速递新发突发、热带与寄生虫病

系统性筛选鉴定广谱抗人致病性脑炎微孢子虫抑制剂:硝唑尼特体外无活性

Systematic screening identified broad-spectrum inhibitors of human-pathogenic Encephalitozoon species and revealed no in vitro activity of nitazoxanide.
PubMed 文献 · J Antimicrob Chemother · 2026-01-01

研究利用MMV开放获取的Pandemic Response Box中400种化合物,以1 µM浓度对兔脑炎微孢子虫、肠脑炎微孢子虫和何氏脑炎微孢子虫进行ELISA筛选。初筛发现8种化合物有 promising 效果,曲美替索(trimetrexate)活性最强(IC50 < 1 µM,选择性指数 > 100),而硝唑尼特在最高测试浓度2 µM下对三种虫均未达到50%生长抑制。结论提示曲美替索是最有前景的候选药物,硝唑尼特在测试条件下无活性,对其治疗人微孢子虫病的角色提出质疑。

要点

  • 曲美替索对三种脑炎微孢子虫IC50均<1 µM,选择性指数>100
  • 硝唑尼特在2 µM下对三种虫均未抑制50%生长
  • 硝唑尼特治疗人微孢子虫病的体外证据不支持

核心结论

  • 曲美替索是进一步抗微孢子虫探索最有前景的候选化合物。
  • 硝唑尼特在测试条件下未显示可检测活性,对其治疗人微孢子虫病的角色提出质疑。

研究设计与样本

  • 筛选MMV提供的Pandemic Response Box中400种化合物。
  • 以1 µM浓度对兔脑炎微孢子虫、肠脑炎微孢子虫和何氏脑炎微孢子虫进行ELISA法初筛。
  • 对入选化合物进一步评估体外细胞毒性和IC50值。

主要发现

  • 初筛显示8种化合物对三种微孢子虫有 promising 效果。
  • 曲美替索对三种虫的IC50值均<1 µM,选择性指数>100。
  • Triapine活性中等,IC50值范围为1至2 µM。
  • 硝唑尼特在最高测试浓度2 µM下对三种虫均未达到50%生长抑制。

临床怎么用

  • 体外结果提示曲美替索值得进一步开发用于微孢子虫病。
  • 硝唑尼特在测试条件下无活性,临床选用需谨慎评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Microsporidia are obligate intracellular eukaryotic pathogens infecting a wide range of vertebrate and invertebrate hosts. Therapeutic options for microsporidiosis remain limited in both human and veterinary medicine. OBJECTIVES: The goal was to screen the 400 compounds of the open-access Pandemic Response Box, provided by the Medicines for Malaria Venture foundation, for their anti-microsporidia activity. METHODS: The compounds were screened at 1 µM against Encephalitozoon cuniculi, E. intestinalis and E. hellem using an ELISA-based assay. Selected compounds were further evaluated by determining their in vitro cytotoxicity and their IC50 values. RESULTS: Preliminary screening revealed promising efficacy of eight compounds against the three species. Trimetrexate was the most active compound, with IC50 values < 1 µM and selectivity index > 100 for all three species. Triapine exhibited intermediate activity, with IC50 values ranging from 1 to 2 µM. Nitazoxanide failed to achieve 50% growth inhibition at the highest concentration tested (2 µM) against any of the three species. CONCLUSIONS: Trimetrexate emerged as the most promising candidate for further anti-microsporidia exploration, whereas nitazoxanide showed no detectable activity under the conditions tested, questioning its role in the treatment of human microsporidiosis.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Poirier P, Moniot M, Bonnin V, et al. Systematic screening identified broad-spectrum inhibitors of human-pathogenic Encephalitozoon species and revealed no in vitro activity of nitazoxanide. J Antimicrob Chemother. 2026. PMID: 42720089. doi:10.1093/jac/dkag319

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。